Product Description: D-AP5 (D-APV) is a selective and competitive NMDA receptor antagonist with a Kd of 1.4 μM. D-AP5 (D-APV) inhibits the glutamate binding site of NMDA receptors[1][2].
Applications: Neuroscience-Neurodegeneration
Formula: C5H12NO5P
Citations: Biomed Pharmacother. January 2022, 112446./Brain Behav Immun. 2023 Jun 5;S0889-1591(23)00141-1./Brain Res. 2019 Dec 15;1725:146487./Cell Death Discov. 2020 Sep 17;6:87./CNS Neurosci Ther. 2022 Nov 15./Environ Sci Technol. 2023 Aug 9./Exp Brain Res. 2023 Oct 16./Front Pharmacol. 2022 Jun 9;13:888308./J Neurochem. 2022 Jul 1./J Neuroinflammation. 2024 Mar 26;21(1):76./Neural Plast. 08 Jul 2021./Neurochem Int. 2023 Jul 24;105587./Research Square Print. August 24th, 2022./Sci Rep. 2024 Aug 20;14(1):19337./Sens Actuators B Chem. 2020, 129190./Theranostics. 2021 Mar 4;11(10):4616-4636./Theranostics. 2023 May 11;13(9):2946-2961./Int J Biol Macromol. 2024 Oct 28:136767.
References: [1]Davis S, et al. The NMDA receptor antagonist D-2-amino-5-phosphonopentanoate (D-AP5) impairs spatial learning and LTP in vivo at intracerebral concentrations comparable to those that block LTP in vitro. J Neurosci. 1992 Jan;12(1):21-34./[2]Morris RG, et al. N-methyl-d-aspartate receptors, learning and memory: chronic intraventricular infusion of the NMDA receptor antagonist d-AP5 interacts directly with the neural mechanisms of spatial learning. Eur J Neurosci. 2013 Mar;37(5):700-17./[3]R H Evans, et al. The effects of a series of omega-phosphonic alpha-carboxylic amino acids on electrically evoked and excitant amino acid-induced responses in isolated spinal cord preparations. Br J Pharmacol. 1982 Jan;75(1):65-75.
CAS Number: 79055-68-8
Molecular Weight: 197.13
Compound Purity: 99.94
Research Area: Neurological Disease
Solubility: DMSO : < 1 mg/mL (ultrasonic;warming;heat to 60°C)/Ethanol : < 1 mg/mL (ultrasonic)/H2O : 2 mg/mL (ultrasonic)
Target: iGluR
English
Deutsch
